Table 1 Initial and salvage patient characteristics
Characteristics | At initial presentation | At salvage | |
|---|---|---|---|
Age (years) | Mean 60 | Mean 65 | |
Range 50 - 77 | Range 60 - 80 | ||
KPS | Mean 80 | Mean 80 | |
Range 70 - 90 | Range 70 - 90 | ||
PSA ng/ml | Mean 17.3 | Mean 5 | |
Median 10.7 | Median 3.7 | ||
Range 4 - 121 | Range 1.1 - 30 | ||
PSA ng/ml | Patients (%) | Patients (%) | |
< 10 ng/ml | 26 (46%) | 51 (91%) | |
10-20 ng/ml | 18 (32%) | 4 (7%) | |
> 20 ng/ml | 12 (22%) | 1 (2%) | |
Gleason score | Patients (%) | Patients (%) | |
≤ 3 + 3 | 37 (66%) | 9 (16%) | |
3 + 4/4 + 3 | 16 (29%) | 14 (25%) | |
≥ 4 + 4 | 3 (5%) | 8 (14%) | |
Unavailable | 25 (45%) | ||
T stage | Patients (%) | Patients (%) | |
T1c | 23 (41%) | ||
T2 | 26 (46%) | ||
T3 | 7 (13%) | ||
Unknown | |||
Recurrent | 56 (100%) | ||
D’Amico risk group | Patients (%) | Patients (%) | |
Low | 24 (43%) | ||
Intermediate | 16 (28.5%) | ||
High | 16 (28.5%) | ||
Unknown | |||
Radiation treatment | Patients (%) | Patients (%) | |
EBRT | 46 (82.%) | ||
< 72 Gy | 24 (43%) | ||
> 72 Gy | 22 (39%) | ||
LDR-BQT | 10 (18%) | 37 (66%) | |
HDR-BQT | 19 (34%) | ||
Time to biochemical relapse | Patients | Patients | |
(ASTRO/Phoenix definition) | ASTRO | PHOENIX | |
< 24 months | 6 (11%) | 4 (7%) | |
> 24 months | 50 (89%) | 52 (93%) | |
Androgen deprivation therapy | Patients (%) | Patients (%) | |
Yes | 26 (46%) | 15 (27%) | |
No | 30 (54%) | 41 (73%) | |
Time to nadir post-RT/BQT | |||
≤ 6 months | 15 (26.8%) | ||
6 – 12 months | 7 (12.5%) | ||
> 12 months | 34 (60.7%) | ||
Nadir PSA post-radiation | Mean 0.6 ng/ml | Mean 0,5 ng/ml | |
Median 0.5 ng/ml | Median 0.16 ng/ml | ||
Range 0.001 – 3 ng/ml | Range 0.001 – 2.9 ng/ml | ||